Clinical Trials

477 enrolled 2 FDA

Pancreatic Neoplasms, Colorectal Neoplasms

NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

64 enrolled

Gastric Adenocarcinoma

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05480384 2026-04-01

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

1 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04639219 2026-03-23

DPT01

102 enrolled 18 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT06048718 2026-03-10

TUXEDO-4

28 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

62 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04739761 2026-02-11

DESTINY-B12

Phase 1/2 Active not recruiting

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05633979 2026-01-20

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

17 enrolled

Breast Neoplasms

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT04556773 2025-12-17

DB-08

138 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05704829 2025-11-19

ADAPTHER2-IV

402 enrolled

Recurrence

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

115 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

524 enrolled 11 charts 2 FDA

Breast Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05246514 2025-08-28

DL-05

72 enrolled 16 charts

Thoracic

HER2-mutant Non-Small Cell Lung Cancer

NCT05765851 2025-05-11

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

78 enrolled

Breast Neoplasms

NCT04622319 2025-05-09

DESTINY-Breast05

1,600 enrolled

HER2-Positive Primary Breast Cancer

NCT05710666 2024-08-05

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

11 enrolled